Abstract | PURPOSE: METHODS: RESULTS: Chemo (n=58) and no-chemo (n=70) patients had similar age (P=0.13), gender (P=0.67), body mass index (P=0.46), American Society of Anesthesiologists class (P=0.67), preoperative tumor stage (P=0.16), type of surgery (P=0.76), and postoperative complications. The no-chemo group had greater complete pathologic response (n=34, 48.6% vs. n=14, 24.1%). After prolonged follow-up, local recurrence (P=1), disease-free survival (P=0.41), and overall survival (P=0.52) were similar. Oncologic benefits of adjuvant chemotherapy were especially questionable for patients with complete pathologic response (chemo vs. no-chemo, local recurrence at 5 years: 0 vs. 2.9%, P>0.99), disease-free (79.1% vs. 88%, P=0.51), and overall survival (90.9% vs. 95.2%, P=0.41). CONCLUSIONS:
|
Authors | Ravi P Kiran, Hasan T Kirat, Adele N Burgess, Pasha J Nisar, Matthew F Kalady, Ian C Lavery |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 19
Issue 4
Pg. 1206-12
(Apr 2012)
ISSN: 1534-4681 [Electronic] United States |
PMID | 21935748
(Publication Type: Journal Article)
|
Topics |
- Chemoradiotherapy, Adjuvant
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Humans
- Lymph Nodes
(pathology)
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Postoperative Care
- Rectal Neoplasms
(mortality, pathology, therapy)
- Survival Rate
- Treatment Outcome
|